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ABSTRACT
Background. Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome(DS) are two types of childhood
epilepsy syndromes that are often resistant to traditional anti-epileptic drug (AED) regimens. With the
development of a pharmaceutical grade purified cannabidiol (CBD), there has been increasing interest in
its utility for treatment of epilepsy. We conducted a systematic review to explore the efficacy of CBD in
reducing seizure frequency when added to traditional AED regimens in those who are considered to
have treatment resistant epilepsy (TRE).
Method. A search of PubMed was performed in September 2020 using the terms “cannabidiol”,
“Lennox-Gastaut Syndrome”, “Dravet Syndrome”, and “epilepsy” with a filter for clinical trials and
randomized control trials (RCTs). Six studies were selected that evaluated the efficacy of pharmaceutical
grade cannabidiol as adjuvant therapy in treating treatment resistant epilepsy. Treatment efficacy was
measured by seizure frequency and was documented similarly among trials to allow for relative
comparison between studies. Two of the six studies looked at long-term safety in addition to efficacy,
which provided a more clinical application for the drug.
Results. Of the six studies analyzed, the mean percent reduction in all seizure frequency from baseline
was 41.5% in the treatment groups and 17.4% in the placebo groups. Of the two studies looking at longterm safety data, an average of 92.1% of participants experienced an adverse event.
Conclusion. CBD as an adjuvant medication for treatment resistant epilepsy may have potential to
reduce seizure frequency, but not without the risk of adverse effects. Additional research with larger
sample sizes is warranted to better understand its utility and safety.
INTRODUCTION
Epilepsy, a chronic seizure disorder, is a condition that plagues nearly 3 million adults and
470,000 children nationwide.1 It is defined as the clinical expression of a sudden abnormal and sustained
electrical disturbance in the cerebral cortex, which can be readily seen on electroencephalography
(EEG).2 Seizures are typically self-limiting lasting no more than a few minutes, and present with a variety
of clinical manifestations dependent on the type of seizure. Seizures can be classified by their onset, the
patient’s level of awareness, and presence or absence of motor symptoms. Unfortunately, those with
epilepsy disorders can experience significant health consequences in addition to social, behavioral, and
economic consequences.
It is estimated that 20-40% of patients with epilepsy will experience treatment-resistant, or
refractory, epilepsy. This equates to nearly 400,000 individuals who are affected in the United States
alone.3 Treatment-resistant epilepsy (TRE) contributes to increasing medical costs, a decreased quality
of life, and potentially a lifetime of epilepsy-related disability. There is no clinical definition of TRE, but it
is generally considered in patients who have failed at least three anti-epileptic drugs (AEDs). Alternative
or adjuvant therapies that are currently considered in patients with TRE include vagus nerve stimulation,
the ketogenic diet, deep brain stimulation, surgery, and now more recently cannabidiol.3
Cannabidiol is an abundant non-psychoactive cannabinoid found in cannabis that may exhibit
anticonvulsant properties, although the mechanism of action is not well understood. With the recent
FDA approval of the first plant-derived cannabinoid prescription in June of 2018, the need for

determining the utility of cannabidiol in epilepsy is imperative. The FDA-approved cannabidiol drug,
Epidiolex, is currently available as an oral solution and is approved for use in treatment of seizures in
LGS, DS, or tuberous sclerosis complex in patients who are one years of age or older.
Lennox Gastaut Syndrome (LGS) and Dravet Syndrome (DS) are two types of childhood epilepsy
that are often treatment resistant. They have been the focus of much of the research into cannabidiol.
DS occurs by 12 months of age and is associated with progressive developmental and cognitive decline.
It is caused by mutations in the SCN1A sodium channel, 95% of which are de novo. Although rare
(incidence ranges from 1 in 15,700 to 1 in 40,000), the consequences are severe. LGS peaks between
ages 3-5.4 Structural brain abnormalities are the cause in the majority of cases, but it can also result
from hypoxia, infection, and chromosomal abnormalities (uptodate). LGS occurs in 2 in 100,000
children.5 Both syndromes are characterized by significant reductions in quality of life.
With the increasing interest in cannabis and cannabis-derived products for use in medicine, it is
important to understand the efficacy and safety profile of these types of pharmaceuticals. This metaanalysis aims to understand the utility of purified cannabidiol used as an adjuvant therapy in TRE by
looking at reduction in seizure frequency. This will help determine if cannabidiol is an effective
treatment for patients experiencing refractory epilepsy.
CLINICAL QUESTION
Among children and adults with treatment resistant epilepsy, does pharmaceutical cannabidiol
used in addition to standard medical therapy significantly reduce seizure frequency?
METHODS
Pubmed and Google Scholar were searched in September 2020 using the terms “cannabidiol,”
“Lennox-Gastaut Syndrome,” “Dravet Syndrome,” and “epilepsy.” Only clinical trials and randomized
control trials were included, and meta-analyses and literature reviews were excluded. Thirty-three
studies were found, nineteen of which were excluded due to irrelevance. Irrelevant findings included
articles on the pharmacokinetics of cannabidiol and Phase 1/2 trials, among others. Fourteen full-text
articles were assessed for eligibility. Eight were excluded due to the inadequacy of the sample size in
randomized-control and prospective trials or due to bias in the study design. Six studies were deemed
appropriate for analysis. The selection process is available in Figure 1.

Figure 1. PRISMA flow diagram outlining article selection process.

RESULTS
Study #1: Devinsky et al. Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome.6
Study Objective:
To quantify the percent change from baseline daily frequency of drop seizures to frequency of drop
seizures during the treatment period with Cannabidiol.

Study Design:
Participants: 225 patients between the ages of 2 and 55 were enrolled in a randomized, placebocontrolled trial. Patients had documented LGS with an electroencephalogram showing a pattern of slow
(<3.0 Hz) spike-and-wave complexes consistent with the disease. Patients also had at least 2 seizures per
week during the 28 day baseline period and were on stable medication doses and nonpharmacologic
therapy. Full patient inclusion and exclusion criteria is in Table 1.
Intervention: Oral cannabidiol at 20mg/kg or 10mg/kg or matching placebo at equivalent volumes for
either (in addition to stable treatment with other AEDs).
Outcome Measures: The percentage change in drop seizure frequency from the baseline established in
the 28 day run in period. Key secondary outcome measures were identification of patients who had a
≥50% reduction in seizure frequency, the percentage change in all types of seizure frequency, and a
Patient or Caregiver Global Impression of Change (PCGIC) from baseline score.
Randomization and Blinding: Patients were randomized into blocks of six before being randomized into
the high dose treatment, low dose treatment, high dose placebo, and low dose placebo in a 2:2:1:1
ratio. This randomization was performed by a computer program run by an independent statistician. The
trial was double-blinded.
Statistical Analysis: The authors estimated that a minimum of 50 patients per trial would achieve 80%
statistical power to detect a difference of 32 percentage points in reduction from cannabidiol to placebo
at a two-tailed alpha level of 5%. This number was exceeded during recruitment. The authors used a
Wilcoxon rank-sum test to analyze the primary outcome and a Hodges-Lehmann approach to estimate
the median difference between the groups. In order to test multiple outcomes with a limited false
positive rate, they used a hierarchical gate-keeping procedure in which each subsequent outcome was
only tested if the prior one achieved significance. The percentages of patients that responded to
treatment (classified by ≥50%, ≥75%, and 100% decreases in seizure frequency) were then stratified by
age group using a Cochran-Mantel-Haenszel test. Other secondary outcomes are available in the study
but were not included here due to relevance.
Table 1. Inclusion and Exclusion Criteria for Participation in Study 1.

Devinsky et al.
(2018A)

Inclusion

Exclusion

● Diagnosed LGS
● Ages 2-55 years old
● Electroencephalogram showing a pattern of slow
(<3.0 Hz) spike-and-wave complexes
● At least two types of generalized seizures, including
drop seizures, for at least the past 6 months
● Taking between 1 and 4 AEDs
● At least 2 seizures per week during the 28 day
baseline period
● Stable medication doses and nonpharmacologic
therapy for 4 weeks during screening and through
the study

● Unstable medical conditions
during 4 weeks before
screening
● History of alcohol or substance
abuse
● Use of cannabis in previous 3
months
● Use of corticotropins in the
previous 6 months
● Current use of felbamate for
less than 1 year

Study Results:
Primary Outcome Measure: The median decrease in drop seizure frequency from baseline was 41.9% in
the 20mg/kg group, 37.2% in the 10mg/kg group, and 17.2% in the placebo group. The estimated
median difference in reduction of the high dose group and placebo was 21.6% with a p-value of 0.005
and a 95% confidence interval of 6.7-34.8. The estimated median difference in reduction between the
10mg/kg and placebo group was 19.2% with a p-value of 0.002 and a 95% confidence interval of 7.7 to
31.2. The estimated median difference in reduction was calculated by using a Hodges-Lehmann
Estimator.
Secondary Outcome Measure: 39% of patients in the high dose (20mg/kg) group, 36% of patients in the
low dose (10mg/kg) group, and 14% of patients in the placebo group had a ≥50% reduction in dropseizure frequency from baseline. The odds ratio for the high dose and placebo group was 3.85 with a pvalue of <0.001 and a 95% CI of 1.75 to 8.47. The odds ratio for the low dose and placebo group was
3.27 with a p-value of 0.003 and a 95% CI of 1.47 to 7.26. The median frequency from baseline of all
seizures dropped 38.4%, 36.4%, and 18.5% in the high dose, low dose, and placebo groups respectively.
According to results from the PCGIC, 57% of patients in the 20mg/kg group improved from baseline, as
did 66% of patients in the 10mg/kg group, and 44% in the placebo group. The odds ratio for the high
dose was 1.83 at significance level of 0.04 and a 95% CI of 1.02 to 3.30 compared to placebo. The odds
ratio for the low dose was 2.57 at significance level of 0.002 and a 95% CI of 1.41 to 4.66 compared to
placebo.
Study Critique:
This study was a well-designed double-blind placebo-controlled trial that utilized a computer
generated block randomization schedule produced by an independent statistician. This contributes to
minimization of confounding variables that could affect study outcomes. Additionally, treatment groups
were similar in size and demographics including age, sex, median number of previous AEDs, and others
had no significant differences. Inclusion and exclusion criteria were clearly stated.
Limitations of this study include a relatively short treatment period of only 12 weeks of
maintenance dosing, reliance on patients or caregivers to provide the number and type of seizures daily,
and several protocol deviations during the trial. Eleven patients that were excluded from the per
protocol analysis set were due to protocol deviations. These protocol deviations include six patients that
received the incorrect dosing schedules and six patients that had deviations from the inclusion/exclusion
criteria listed in Table 1. Additionally, the authors used trial data from patients that did not complete the
study up to the point of withdrawal from the study. This may magnify the efficacy of the drug, rather
than accurately report the effectiveness if side effects are intolerable.

Study #2. Devinsky et al. Trial of Cannabidiol for Drug-Resistant Seizures in Dravet Syndrome.7
Study Objective:
To quantify the effects of cannabidiol in reducing drug-resistant convulsive seizures (failure of two or
more appropriate drug schedules) in patients with Dravet Syndrome over 14 weeks.

Study Design:
Participants: 120 children and young adults ages 2-18 years old with an established diagnosis of Dravet
Syndrome, use of one or more AEDs, and had four or more convulsive seizures during a baseline period
of 28 days. Patients were required to have stable pharmacological and non-pharmacological
interventions for 4 weeks prior to starting the trial. Full inclusion and exclusion criteria can be found in
Table 2.
Intervention: 20mg/kg of cannabidiol solution or matching placebo on top of the participants baseline
use of AEDs.
Outcome Measures: The primary endpoint was the percentage change in convulsive seizure frequency
every 4 weeks from a 28 day baseline period. The treatment length was 14 weeks, including a two week
dose escalation period. Key secondary outcomes included change in Caregiver Global Impression of
Change (CGIC), the number of participants with a ≥25%, ≥50%, ≥75%, and 100% reduction in convulsive
seizure frequency, the reduction in total seizure frequency, the duration of seizures (using the Caregiver
Global Impression of Change in Seizure Duration), and several other metrics of quality of living (such as
sleep).
Randomization and Blinding: 120 patients were randomized at a 1:1 ratio of treatment to placebo. The
trial was double-blinded
Statistical Analysis: The authors estimated that there would be a 32 percentage point difference in the
reduction in convulsive seizures between the treatment and placebo groups. This required 100 patients
for 80% statistical power, which was achieved. The primary endpoint analysis was performed with the
use of the Wilcoxon rank-sum test. The estimated median difference between treatment and placebo
groups, along with the confidence interval, were calculated with the use of the Hodges-Lehmann
Estimator. Data was used from an intention-to-treat protocol. The percentages of patients with grouped
reductions (≥25, ≥50, ≥75, and 100%) were analyzed with the use of the Cochran-Mantel-Haenszel test
to calculate their odds ratios. An ordinal logistic-regression was used to establish the change from
baseline in the CGIC and CGICSD.
Table 2. Inclusion and Exclusion Criteria for Participation in Study 2.

Devinsky
et al.
(2017)

Inclusion

Exclusion

● Male or female aged
2-18yo
● Established diagnosis
of Dravet Syndrome
that is not
completely
controlled by current
AEDs
● Taking 1 or more
AEDs
● Must be
experiencing 4 or

● Patient has clinically significant unstable medical conditions other
than epilepsy
● Patient has had clinically relevant symptoms or a clinically significant
illness in the four weeks prior to screening or randomization, other
than epilepsy.
● Patient has clinically relevant abnormalities in the 12-lead ECG
measured at screening or randomization.
● Patient has any concurrent cardiovascular conditions, which will, in
the investigators opinion, interfere with the ability to read their ECGs.

more convulsive
seizures during the
28 day baseline
observation period
● Patient must have no
clinically relevant
abnormal blood
laboratory levels at
screening or
randomization
● Patient must be
taking one or more
of the following AEDs
at a dose which has
been stable for at
least four weeks:
sodium valproate,
levetiracetam,
clobazam,
topiramate
● All medications or
interventions for
epilepsy, including
ketogenic diet, must
have been table for
four weeks prior to
screening and
patient and caregiver
are willing to
maintain a stable
regimen throughout
the study

● Patient has a history or presence of alcohol or substance abuse
within the last two years prior to the study or daily consumption of
five or more alcohol-containing beverages.
● Patient is currently using or has in the past used recreational or
medicinal cannabis, or synthetic cannabinoid based medications
(including Sativex®) within the three months prior to study entry and
is unwilling to abstain for the duration for the study.
● Patient has (in the investigator’s opinion) a clinically significant
postural drop in systolic blood pressure at screening or
randomization.
● Patient has ingested alcohol in the 24 hour period prior to the first
study visit and/or is unwilling to abstain from drinking alcohol
throughout the treatment period.
● Patient has consumed grapefruit or grapefruit juice three days prior
to screening and/or is unwilling to abstain from consuming these
during the study.
● Patient has any known or suspected hypersensitivity to cannabinoids
or any of the excipients of the investigational medicinal product
(IMP)(s).
● Female patients of child bearing potential and male patients whose
partner is of child bearing potential, unless willing to ensure that they
or their partner use effective contraception, for example, oral
contraception, double barrier, intrauterine device, during the study
and for three months thereafter.
● Female patient who is pregnant, lactating or planning pregnancy
during the course of the study and for three months thereafter.
● Patients who have been part of a clinical trial involving an
investigational product in the previous six months.
● Any other significant disease or disorder which, in the opinion of the
investigator, may either put the patient at risk because of
participation in the study, may influence the result of the study, or
affect the patient’s ability to participate in the study.
● Patient has significantly impaired hepatic function at Visit A1 or B1
(Alanine aminotransferase (ALT) >5 × upper limit of normal (ULN) or
bilirubin >2 × ULN) OR the ALT or Aspartate aminotransferase (AST)
>3 × ULN and the bilirubin >2 × ULN (or international normalized ratio
>1.5).
● Following a physical examination, the patient has any abnormalities
that, in the opinion of the investigator, would prevent the patient
from safe participation in the study.
● Patients unwilling to abstain from donation of blood during the study.
● There are plans for the patient to travel outside their country of
residence during the study.
● Patient previously randomized into this study. In particular, patients
taking part in Part A of the study cannot enter Part B.

Study Results:
Primary Outcome Measure: The median monthly convulsive seizure frequency decreased from 12.4 at
baseline to 5.9 in the treatment and from 14.9 to 14.1 in the placebo. The median decrease in the
treatment group was 38.9% from baseline. The placebo group decreased 13.3% from baseline.The
adjusted mean decrease between placebo and treatment was 22.8% at a significance level of 0.01 with a
95% CI of -41.1 to -5.4.
Secondary Outcome Measure: CGIC decreased by 1 between the treatment and placebo (p=0.02). The
odds ratio for a ≥25% reduction was 2.10 (p=0.05); OR for a ≥50% reduction was 2.00 (p=0.08); OR for a
≥75% reduction was 2.21 (p=0.11). 3 patients in the treatment group achieved 100% reduction, while
none in the placebo group did. Therefore an Odds Ratio could not be calculated. Total seizure frequency
decreased 19.2% in the treatment compared to the placebo (p=0.03).
Study Critique:
This study was a double-blind, placebo-controlled trial that utilized randomization performed by
an independent statistician to help control for bias and confounding variables. This study also did a good
job of outlining baseline characteristics of both treatment groups to ensure that there were no
significant differences in demographics between groups. Part A of this study, published elsewhere, has
already established the pharmacokinetics and safety of cannabidiol on a similar patient population.
Although the inclusion criteria is explicitly stated in the study, exclusion criteria was only
included in the supplemental appendix. Of the exclusion criteria, there are multiple measures that are
up to the subjective opinion of the investigator, which has the potential to lead to inconsistencies in the
types of patients who are included or excluded. This study is also limited in the fact that outcomes rely
solely on the accuracy of recording seizure frequency and seizure type by the patient themselves or a
designated caregiver, which may contribute to reporting bias.

Study #3. Devinsky et al. Cannabidiol in Patients with Treatment Resistant Epilepsy: An Open-Label
Interventional Trial.8
Study Objective:
To establish the safety and tolerability of CBD and to quantify the median percentage change in the
mean monthly motor seizure frequency.
Study Design:
Participants: 162 patients were enrolled in the safety analysis set and 137 were included in the
intention-to-treat efficacy analysis. Patients were ages 1-30 years old, had intractable childhood
epilepsy, ≥4 or more motor seizures in a 28 day baseline period, and were on stable pharmacologic and
nonpharmacologic interventions for the 28 days before the trial began. Inclusion and exclusion criteria
were largely determined by the treatment site, but a common list of exclusion criteria can be found in

Table 3. Patients were excluded from the efficacy analysis set due either age <1 year old, progressive
Neuronal ceroid lipofuscinosis disorders, or the absence of motor seizures.
Intervention: Cannabidiol at 2-5mg/kg titrated to tolerance or a maximum dose of 25mg/kg/day. Some
sites allowed up to 50mg/kg/day.
Outcome Measures: Every two weeks, adverse effects were assessed using a Liverpool Adverse Events
Prolife or the Pediatric Epilepsy Side Effects Questionnaire. Labs were drawn at 4, 8, and 12 weeks. The
efficacy analysis portion involved recording seizures by parents and caregivers in a diary, which
researchers reviewed at each 4 week visit. This was used to calculate the change in median monthly
motor (and non-motor) seizure frequency.
Randomization and Blinding: Unblinded and without a placebo. Patients were not randomized to receive
treatment, and it is unclear the patient population that qualified for the study compared with the
population size of those that enrolled.
Statistical Analysis: The authors used a Mann-Whitney U test to calculate the percentage change in the
frequency of motor seizures. The authors also performed multiple logistic regressions to adjust for the
use of valproate and clobazam and response, as those drugs are metabolized by CYP enzymes inhibited
by CBD.
Table 3. Inclusion and Exclusion Criteria for Participation in Study 3.

Devinsky et al.
(2016)

Inclusion

Exclusion

● Ages 1-30 years old
● Intractable childhood-onset epilepsy
● 4 or more countable seizures with a
motor component per 4 week period
● Receiving stable doses of antiepileptic
drugs, vagus nerve input, and diet (if
applicable) for at least 4 weeks before
enrollment
● Inclusion criteria varied dependent on
site specific protocols, however, the
above inclusion criteria were consistent
amongst all 11 sites

● Previous or current treatment with cannabisbased therapy
● Most sites excluded patients with baseline
liver, renal, or hematological abnormalities
● Most sites excluded patients who had
felbamate or vigabatrin within 6 months of
first clinic first

Study Results:
Primary Outcome Measure: 79% of patients (128 out of 162) reported adverse events, such as
somnolence, changes to appetite, gastrointestinal distress, convulsions, fatigue, status epilepticus,
sedation, gait abnormalities, and changes in antiepileptic medication concentrations. The major adverse
events were somnolence (25% of patients), decreased appetite (19% of patients), and diarrhea (19% of
patients). 30% (48 of 162) patients reported serious adverse events.
Secondary Outcome Measure: The median monthly frequency of motor seizures at baseline was 30 (IQR
11.0-96.0). The median monthly frequency at 12 weeks of treatment was 15.8 (IQR -64.70 to 0), for a
median decrease of 36.5% in motor seizure frequency. The median change in all seizure frequency (not
just motor) was 34.6% (IQR -66.7 to -9.8).

Study Critique:
As with any open-label type study, there is a lack of blinding of subjects and researchers, which
can significantly contribute to reporting bias from patients or their caregivers who are responsible for
documenting the frequency of seizures. This type of study also has the potential to magnify the effects
of the intervention, considering there is no placebo comparison. Additionally, there was no standard
established dose for each patient, as doses were continued until intolerance or to a set maximum dose.
The maximum dose at some sites was 25mg/kg and 50mg/kg at other sites. This inconsistency may allow
those that tolerate the medication to reap the most benefits. This study took place at 11 different sites
in the USA allowing for a variety of different patient populations from different areas, however, all
inclusion criteria was not standard amongst all clinical sites. There were four criteria that had to be met
at each site, but there were additional site-specific protocols being used. Exclusion criteria was clearly
stated. Lastly, this study may be useful for understanding safety of cannabidiol, however, a randomized
controlled trial would be more beneficial in determining efficacy.

Study #4. Laux et al. Long-term Safety and Efficacy of Cannabidiol in Children and Adults with Treatment
Resistant Lennox-Gastaut syndrome or Dravet Syndrome: Expanded Access Program Results.9
Study Objective:
To quantify the median percentage change in the mean monthly motor seizure frequency and establish
the safety and tolerability of CBD.
Study Design:
Participants: 607 patients were enrolled (152 LGS/DS and 455 other TREs). Of the 152 LGS/DS patients,
147 were included in the efficacy analysis set and 152 were included in the safety analysis set. Of the
455 other TREs, 433 patients were included in the efficacy analysis set and all were included in the
safety analysis set. Full inclusion and exclusion criteria can be found in Table 4.
Intervention: CBD 2-10mg/kg/day titrated up to 25-50mg/kg/day depending on the investigating site for
144 weeks.
Outcome Measures: The primary endpoint was the percentage change in monthly seizure frequency
from baseline. Patients were seen in clinic every 2-4 weeks, and efficacy outcomes were measured at
12, 24, 48, 72, and 96 weeks. Safety measures were recorded and assessed by the treating physician
using the Medical Dictionary for Regulatory Activities (MDRA).
Randomization and Blinding: This trial is open-label and neither the patient nor the provider were
blinded. There was no placebo or alternative therapy, so patients were not randomized.
Statistical Analysis: Any patient receiving ≥1 dose of CBD and ≥1 post-baseline visit were included in the
safety analysis set. The efficacy set was analyzed using intention-to-treat, as any patient with >0 seizures
at baseline and ≥1 visit postbaseline were included. The change in frequency was calculated by
multiplying the weekly motor seizure frequency by 4. This number was subtracted then divided by

baseline monthly motor seizure frequency and multiplied by 100. The median reduction from median
was then calculated.
Table 4. Inclusion and Exclusion Criteria for Participation in Study 4.

Laux (2019)

Inclusion

Exclusion

● Children and adults with diagnosed TRE
● Receiving stable doses of AED for at
least 4 weeks before enrollment
● Inclusion criteria varied depending on
site specific protocols, however, the
above inclusion criteria were consistent
amongst each site.

Varied by site-specific protocols

Study Results:
Primary Outcome Measure: Baseline monthly motor seizures were 41 for the LGS/DS subgroup and 44
for the Other TRE group. At 12 weeks, the median reduction in major motor seizure frequency from
baseline in the LGS/DS was 50% (n total=108) in the efficacy analysis set. At 96 weeks, the median
reduction in major motor seizure frequency from baseline was 48% (n total=53). Median treatment
duration for this group was 80.1 weeks (IQR 20.7-107.7) by the end of the study. In the other TREs
group, there was a median reduction in monthly major motor seizures from baseline of 53% (n
total=235) at 12 weeks. At 96 weeks, there was a 41% median reduction in major motor seizures from
baseline (n total=59). In the LGS/DS group, 53% of patients (n total = 108) had a ≥50% reduction in major
motor seizures from baseline at 12 weeks in the EAS. At 96 weeks, this number at 45% of patients. In the
other TREs, 52% of patients (n total = 235) had a ≥50% reduction in major motor seizures at 12 weeks. At
96 weeks, 42% of patients had a ≥50% reduction in major motor seizures (n total = 59).
Secondary Outcome Measure: 91% of LGS/DS patients had an adverse event, of which 41% experienced
a serious adverse event. The three most common adverse events were somnolence, convulsions, and
diarrhea. The other TRE group data was not reported in this study.
Study Critique:
Strengths of this study include a large sample size of 607 patients, which contributes to greater
statistical power and decreases the potential for Type II error. Additionally, this study had a lengthy 96week long treatment period, which may be more useful in demonstrating long-term safety and efficacy
and applicability to clinical practice than some of the shorter studies. One caveat is that, of the 433
patients included in the other TRE efficacy set, 136 withdrew during the study. 87 of these withdrew due
to lack of efficacy. By the end of the study at 96 weeks, there were only 59 participants reporting major
motor seizures in the other TRE group (compared to 53 of 108 patients in the LGS/DS group).
This study is limited by the fact that it is an open-label trial without blinding or a placebo
comparison, and as mentioned above, can contribute to bias and magnification of treatment effect. This
study listed limited inclusion criteria, but there was no exclusion criteria explicitly stated in either the
study or the appendix. Additionally, this study appears to have used some of the same patients as

Devinsky 2016, which would most likely only include patients who experienced a benefit with treatment
in the previous trial, which could also magnify treatment benefit. Lastly, the treatment dose that was
used was not standardized. Patients could receive a dose anywhere up to 50mg/kg dependent on
tolerability.

Study #5. Devinsky et al. Long-term Cannabidiol Treatment in Patients with Dravet Syndrome: An Openlabel Extension Trial.10
Study Objective:
Establish the long term safety and efficacy of CBD in the treatment of TREs in patients who have
completed either a randomized control trial or a safety trial.
Study Design:
Participants: 264 patients were recruited, of which only 104 were included in the efficacy population.
This is because 136 patients who were recruited from an ongoing, blinded clinical trial (GWPCARE2) and
another 23 who were recruited from GWPCARE1A were excluded. The latter was excluded from the
efficacy population because its inclusion criteria included a seizure frequency <4 per month. The sample
population was drawn from patients that completed GWPCARE1A (titled Randomized, dose-ranging
safety trial of cannabidiol in Dravet syndrome), GWPCARE1B (titled Trial of Cannabidiol for DrugResistant Seizures in the Dravet Syndrome), or GWPCARE2 (titled Dose-Ranging Effect of Adjunctive Oral
Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome). Full inclusion and
exclusion criteria for these studies can be found in Table 5.
Intervention: CBD titrated from 2.5mg/kg/day to 20mg/kg/day (max 30mg/kg/day based on physician
choice) over a two week period followed by maintenance dosing for the remainder of the study.
Outcome Measures: The primary outcome was safety and tolerability of treatment, based on the
frequency of adverse events, laboratory findings, and vitals. The secondary outcomes were to establish
the change in seizure frequency (convulsive and total), the proportion of patients responding (grouped
by ≥25, ≥50, ≥75, and 100% reductions from baseline), frequency of status epilepticus, and changes in
the Subject/Caregiver Global Impression of Change scale (S/CGIC).
Randomization and Blinding: This trial was open-label and was thus not blinded. The patients, while
randomized in their parent trial, were not randomized as there was no placebo given.
Statistical Analysis: The authors used the patients pre-randomized baseline data from their parent
studies to compare the recorded frequencies.
Table 5. Inclusion and Exclusion Criteria for Participation in Study 5.

Devinsky
(2018B)

Inclusion

Exclusion

● Completed GWPCARE1 A (ages 4-10,
documented uncontrolled DS, 1 or
more AEDs w/ stable dose,

● GWPCARE1 B Exclusion Criteria (other
unstable conditions, relevant abnormalities
on a 12 lead ECG, using or previous use of

experienced fewer than 4 tonic, clonic,
or atonic seizures in past 28 days, all
meds and interventions stable for 4
weeks before enrolling)
● Completed GWPCARE1 B (ages 2-18,
documented uncontrolled DS, ≥4
convulsive seizures in the 4‐week
baseline period, 1 or more AEDs w/
stable dose, all meds and interventions
stable for 4 weeks before enrolling)
● Completed GWPCARE2 (ages 2-18,
documented uncontrolled DS, ≥4
convulsive seizures in the 4‐week
baseline period, 1 or more AEDs at a
stable dose for >4wks, all meds and
interventions stable for 4 or more
weeks)

cannabis in past 3 months, hypersensitivity to
cannabis, part of another clinical trial, travel
outside of country during the study, enrolled
in Part A)
● GWPCARE2 exclusion criteria (other unstable
medical conditions, clinically relevant
symptoms or illness in the 4 weeks prior to
enrolling, previous cannabis use in the last 3
months, known or suspected hypersensitivity
to cannabis, suicidal behavior or ideation)

Study Results:
Primary Outcome Measure: 93.2% of patients (n=264) in the safety analysis set had an adverse outcome.
Serious adverse events were recorded in 77 patients (29.2%). 19 patients (7.2%) withdrew due to
adverse events, such as elevated liver function tests (LFTs). The most common AEs were diarrhea
(34.5%), fever (27.3%), decreased appetite (25.4%), and somnolence (24.6%). The most common serious
adverse events were status epilepticus (11%), convulsion (4.9%), and fever (3.8%).
Secondary Outcome Measure: At week 12, the median reduction in monthly convulsive seizures from
baseline was 37.5% (12.4 reduced to 7.5 seizures per month). At week 48, the median reduction in
monthly convulsive seizures was 44.3%. At week 12, 64% of patients had a ≥25% reduction, 44% of
patients had a ≥50% reduction, 27% of patients had a ≥75% reduction, and 5% of patients had a 100%
reduction. Median reduction of total seizure frequency was 39.% at 12 weeks and 51% at 48 weeks. At
week 48, 85% of patient caregivers reported improvement, up from 82% at 12 weeks.
Study Critique:
This study was limited by the fact that subjects for this trial were recruited from patients who
had already completed a previous CBD trial. It is possible that patients who responded best to the
previous intervention entered into this extension and potentially magnified the treatment effect. Again,
because this study was an open-label trial there was no blinding and a lack of a placebo arm used for
comparison. Finally, the study mentions that patients were instructed to take the drug consistently with
respect to meal times, but this information was not recorded so the prandial state of patients in regards
to their dosing is unknown and may have influenced metabolism of the drug.
Strengths of this study include a large sample size of 278 patients and a much longer treatment
duration than previous studies (274 days), providing more information on safety and long-term efficacy
of the drug. Inclusion and exclusion criteria were clearly stated in the study and the patient populations
were well-balanced between genders.

Study #6. Thiele et al. Cannabidiol in Patients with Seizures Associated with Lennox-Gastaut Syndrome
(GWPCARE4): A Randomised, Double-blind, Placebo-controlled Phase 3 Trial.11
Study Objective:
To assess the safety and efficacy of CBD as an adjuvant therapy in the treatment of drop seizures in LGS.
Study Design:
Participants: 171 patients were recruited. Inclusion criteria included ages 2-55 years old, diagnosed LGS,
slow (<3 Hz) spike-and-wave EEG, more than 1 type of generalized seizure, ≥2 drop seizures per week,
stable on pharmacological and nonpharmacological interventions for 4 weeks prior, and failure of at
least two AEDs. Full inclusion and exclusion criteria can be found in Table 6.
Intervention: Patients received 20mg/kg per day or a matching placebo.
Outcome Measures: The primary outcome assessed was the median percentage change in the frequency
of monthly drop seizures compared to baseline over a 14 week treatment period. Secondary outcomes
included the percentage of patients that reduced monthly drop seizures ≥50%, the percentage decrease
in total seizure frequency compared to baseline, and the change in Patient and Caregiver Global
Impression of Change (PCGIC) at the end of the trial.
Randomization and Blinding: Each patient received a unique number, which was then used to randomize
them in a 1:1 ratio to receive either cannabidiol or a matching placebo. An independent statistician
stratified patients by age brackets to ensure an equal randomization. Patients, providers, and
investigators were masked throughout the trial.
Statistical Analysis: The authors estimated that 100 patients (50 per group) were needed to achieve
≥80% statistical power with a two-tailed alpha level of 0.05. They were well over that. The authors used
intention-to-treat analysis, which was defined as any patient that received ≥1 doses of CBD and had
postbaseline data. The data was not normally distributed, so the authors used non-parametric tests to
analyze the percentage change in seizure frequency. A Wilcoxon rank-sum test was used to assess the
median percentage change in monthly frequency of drop seizures and the Hodges-Lehmann method
was used to estimate median difference and 95% CI between the treatment and placebo groups.
Secondary endpoints were tested in a hierarchical manner in that the subsequent hypothesis was only
tested if significance was achieved in the prior one. The Cochran-Mantel-Haenszel test was used to
generate an age stratified odds ratio for the proportion of patients with a ≥50% reduction in drop
seizure frequency. Total seizure frequency change was also analyzed using a Wilcoxon rank-sum and
Hodges-Lehmann method. Finally, the authors used an ordinal logistic regression model to compare
baseline and treatment PCGIC scores.
Table 6. Inclusion and Exclusion Criteria for Participation in Study 6.

Thiele (2018)

Inclusion

Exclusion

● Ages 2-55 years old
● Diagnosed LGS

● Unstable illness other than epilepsy in 4
weeks prior to screening or randomization

● History of slow <3 Hz spike and wave
patterns on EEG
● Evidence of more than 1 type of
generalized seizure for at least 6
months
● At least 2 drop seizures per week
during 4 week baseline
● Not responsive to at least 2 AEDs

● History of alcohol or substance abuse
● History of cannabis use
● Use of corticotropins in previous 6 months
● Taking felbamate for <1 yr prior
● Positive urine THC
● Pregnant/lactating/or planning on becoming
pregnant

Study Results:
Primary Outcome Measure: There was an estimated median change in monthly drop seizure frequency
of 17.21% at a significance level of 0.0135 and a 95% CI of -30.32 to -4.09 during the 14 week trial. The
median percentage change in drop seizure frequency from baseline in the CBD group was 43.9% (IQR
was -69.6 to -1.9%). In the placebo group, the reduction was 21.8% (IQR was -45.7 to 1.7%).
Secondary Outcome Measure: 44% (n=38) of patients in the cannabidiol group had a ≥50% reduction in
drop seizure frequency from baseline, compared to 24% (n=20) of patients in the placebo group. This
gives an OR of 2.57, 95% CI of 1.33-4.97 and a p-value of 0.0043. There was also an estimated median
21.1% decrease in total seizure frequency between the groups (95% CI of -33.3 to -9.4, p=0.0005). Lastly
58% of patients (n=49) in the CBD group had increased PCGIC compared to 34% of patients (n=29) in the
control group.
Study Critique:
This study was a well-designed randomized, double-blind, placebo-controlled trial performed to
minimize bias and confounding variables. The randomization was achieved using an interactive voice
response system and randomization schedule produced by an independent statistician. Inclusion and
exclusion criteria were clearly stated in the study. Both the treatment group and placebo group had
similar demographics including mean age, stratified age groups, gender, race, region, AED status,
current AEDs, other concomitant interventions, and monthly frequency of seizures at baseline.
Although this study concluded that cannabidiol is efficacious in the treatment of LGS-associated
seizures, it only examined one dose of cannabidiol and therefore dose-related responses or adverse
effects were not examined. The study also had poor ethic diversity amongst treatment and placebo
groups, with 90% of participants being caucasian, and may reflect inadequate variability in the
demographics of the various study sites. This study used a secondary endpoint of suicidal ideation using
the Columbia Suicide Severity Rating Scale (C-SSRS), however, they did not take into consideration that
many patients had cognitive impairment and this scale may not have been applicable to these patients.

Table 7. Overview of the studies discussed in this review.
Devinsky et al.
2018(A)

Devinsky et
al. (2017)

Devinsky et
al. (2016)

Laux (2019)

Devinsky (2018B)

Thiele
(2018)

Study
Style

RCT

RCT

Prospective,
open-label

Prospective,
open-label

Prospective,
open-label

RCT

Objective

To quantify
the percent
change from
baseline daily
frequency of
drop seizures
to frequency
of drop
seizures
during the
treatment
period with
Cannabidiol.

To quantify
the effects of
cannabidiol in
reducing drugresistant
convulsive
seizures in
patients with
Dravet
Syndrome
over 14
weeks.

To establish
the safety
and
tolerability
of CBD and
to quantify
the median
percentage
change in
the mean
monthly
motor
seizure
frequency.

To quantify
the median
percentage
change in the
mean
monthly
motor
seizure
frequency
and establish
the safety
and
tolerability of
CBD.

Establish the long
term safety and
efficacy of CBD in
the treatment of
TREs in patients
who have
completed either
a randomized
control trial or a
safety trial.

To assess
the safety
and efficacy
of CBD as an
adjuvant
therapy in
the
treatment
of drop
seizures in
LGS.

Patient
(N)

Placebo=76
10-mg CBD=73
20-mg CBD=76

Placebo=59
CBD=61

137

152 (LGS/DS
SAS)
455 (Other
TREs SAS)

264 (SAS)
104 (EAS)

Placebo=85
CBD=86

Gender
(male)

Placebo=44
(58%)
10-mg CBD 40
(55%)
20-mg CBD=45
(59%)

Placebo=27
(46%)
CBD=35 (57%)

67 (49%)

93 (61% of
LGS/DS)
220 (43% of
other TREs)

50% (133)

Placebo=43
(51%)
CBD=45
(52%)

Mean age
(years)

Placebo
15.3±9.3
10-mg CBD
15.4±9.5
20-mg CBD
16.0±10.8

Placebo
9.8±4.8
CBD 9.7±4.7

10.5

12.8
(LGS/DS)
13.3 (other
TREs)

9.8±4.4

Placebo
15.3±9.8
CBD
15.5±8.7

Follow-up
Period

14 weeks

14 weeks

12 weeks

96 weeks

48 weeks

14 weeks

Dose

10mg/kg CBD,
20mg/kg CBD,
and placebo

20-mg CBD
and placebo
equivalent

Titrated until
intolerance
or max dose

Titrated until
intolerance
or max dose

Mean: 21mg/kg/
day, dose could
be titrated up to

20mg/kg
CBD and
placebo

equivalents

of
25mg/kg/d

of 25-50
mg/kg/d

30mg/kg/day if
tolerated

equivalents

DISCUSSION
LGS, DS, and other types of epilepsy are most commonly managed with one or multiple AEDs.
However, epilepsy syndromes that are classified as treatment resistant do not experience the same
relief of symptoms with AEDs, begging the need for alternative and additional treatment options.
Purified CBD has shown anti-epileptic potential and may benefit those experiencing TRE. The purpose of
this review is to determine if there is any benefit of the addition of CBD to standard treatment therapy
in those with TRE.
The six studies evaluated in this review demonstrated convincing evidence that pharmaceutical
grade CBD, when used in conjunction with a typical AED regimen, can significantly decrease the
frequency of seizures in those with TRE. Two trials included in this review, Laux et. al. and Devinsky
2018B, were extension trials of previous studies. Table 8. summarizes the results of the studies below.
Table 8. Overview of the results of the studies discussed in this review.
Devinsky
(2018A)

Devinsky (2017)

Devinsky (2016)

Laux (2019)

Devinsky
(2018B)

Thiele (2018)

Median
Reduction in
Monthly Drop
Seizure
Frequency (%)*

Median Reduction in
Monthly Convulsive
Seizure Frequency (%)

Median
Reduction in
Monthly Motor
Seizure
Frequency (%)

Median
Reduction in
Monthly
Motor Seizure
Frequency (%)

Median
Reduction in
Monthly
Convulsive
Seizure
Frequency (%)

Median
Reduction in
Monthly
Drop Seizure
Frequency
(%)*

Placebo

17.2

13.3

Not used

Not used

Not used

17.21

CBD (low
dose)

37.2

N/A†

N/A†

N/A†

N/A†

N/A†

CBD (high
dose)

41.9

38.9

36.5

50

37.5

43.9

Duration
(weeks)

14

14

12

12‡

12§

14

Conclusion

Cannabidiol was
associated with
greater
reductions in
the frequencies
of drop seizures
and all seizures
than placebo.

Cannabidiol reduced the
frequency of convulsive
seizures among children
and young adults with
the Dravet syndrome
over a 14-week period
but was associated with
adverse events.
including somnolence
and elevation of LFTs

CBD might
reduce seizure
frequency and
might have an
adequate safety
profile, but RCTs
are needed.

Reductions in
seizure
frequency were
achieved at 12
months and
remained
through the 96
weeks of
observation.

The reduction in
the frequency
of convulsive
and total
seizures due to
CBD use
established in
GWPCARE 1 B
was maintained.

CBD was safe
and effective
in treating
treatment
resistant LGS

*Although the primary endpoint in this study was slightly different (drop vs. convulsive seizures), the

comparison is close as drop seizures are motor seizures. This may leave out atonic seizures, but that
type of seizure presents recording challenges.
†The doses used were approximately 20mg/kg or greater, which is similar to the high doses of CBD in
the other trials.
‡The result from 12 weeks of treatment was used as the sample size (108) was greater than at 96 weeks.
§Although the trial went longer with a greater reduction (37.% vs. 44.3%), the 12 week result was used
for homogeneity.
The average percentage reduction in motor, convulsive, and drop seizure from baseline of
41.45% and a range of 13.50% (minimum effect recorded was 36.50% and maximum effect was 50%)
when using the 3 RCTs and 3 prospective cohort trials. The average percentage change from baseline
from RCTs only was 41.57% (range of 5%; placebo mean reduction of 17.4%); the average change in the
prospective cohorts only was 41.33% (range of 13.5%). Although not placebo controlled, there was little
difference between the average results of the prospective and randomized trials. We interpret this as an
indication that the lack of placebo did not have a large undue influence on the results of the prospective
trials.
We included the two extension trials (Laux et al. and Devinsky 2018B) to examine the practical,
clinical effects of using CBD long-term as these trials were four to eight times longer than the
randomized ones. Laux et al. found that the median reduction in motor in the LGS/DS subgroup was 50%
at 12 weeks and 48% at 96 weeks (with the caveat that the sample was half as large at the end of the
trial). In the other TRE subgroup, the median reduction percentage was 53% at 12 weeks and 41% at 96
weeks (with the caveat that there were roughly one-quarter of the subjects at 96 weeks as at 12 weeks).
While the sample sizes were significantly smaller, we believe that the effect size is still valid as the effect
size decreased, rather than increased; this suggests that disenrollment was not due to antiepileptic
effects but rather the duration of the trial.
In order to fully determine the clinical utility of CBD in TRE, it is important to evaluate the
frequency of adverse events and potential risks for your patient in addition to efficacy. Most participants
in these studies reported having mild to moderate adverse events, with a much smaller proportion
having experienced severe adverse events. The mild to moderate adverse events that were most
frequent included somnolence, decreased appetite, diarrhea, lethargy, vomiting, and pyrexia. Both mild
to moderate and severe adverse events were seen in higher proportion in the CBD treatment groups
compared to placebo. Severe adverse events that were most commonly reported include status
epilepticus, convulsions, and increases in liver transaminases; however, the studies did not consider
status epilepticus to be treatment-related. Elevations in liver transaminases, or liver function tests
(LFTs), were common reasons for withdrawal from the study despite most studies reporting the LFT
elevations to be mild and transient and often resolving spontaneously. It is important to keep in mind
that the participants of these studies are already on multiple AEDs at baseline, with possible dose
adjustments throughout the trial, which may be a large contributing factor to the increase in LFTs. For
example, Valproic Acid, a commonly used AED, poses a risk for hepatotoxicity. The Thiele et. al. study
reported that many of the subjects were on valproate. The Laux et. al. study also reported that of the 22
participants that had elevations in LFT’s, 18 (82%) were also on concomitant valproate. It is also
important to note that CBD is a potent inhibitor of several hepatic enzymes including CYP450, CYP3A4,
and CYP2C19 which are responsible for metabolism of valproate and other anti-epileptic drugs that

many patients were taking throughout the study.12 This gives us reason to believe that the CBD used in
combination with the AEDs, rather than the CBD alone, is a primary culprit for many of the adverse
effects.
Devinsky (2017) was the only study to report the percentage of adverse events that they
considered to be related directly to the treatment drug, which was 75% in the CBD group and 36% in the
placebo group. The OR for experiencing an adverse event with CBD compared to placebo was 3.1, with
an average adverse event rate of 88.6% in CBD treatment groups and 72% in placebo groups. Adverse
event rates specific for each study can be found in Table 9. All deaths that occurred throughout the six
trials were documented as not related to the treatment drug. Overall, CBD was tolerated well by most
patients and withdrawal rates due to adverse effects were low.

Table 9. Overview of adverse event rates

Devinsky
(2018A)

Devinsky
(2017)

Devinsky
(2016)

Laux
(2019)

Devinsky
(2018B)

Thiele
(2018)

% of all-cause AE*
in CBD treatment
groups

89.3

93

79

91

93.2

86

% of all-cause AE in
placebo group

72

75

N/A

N/A

N/A

69

% of serious AE in
CBD treatment
groups

8.7

16.4

12.3

41

29.2

23

% of serious AE in
placebo group

4.7

5.1

N/A

N/A

N/A

4.7

% of LFT elevations
reported in CBD
treatment groups

9

19.6

7

15

31

23.2

% of LFT elevations
reported in
placebo group

0

1.6

N/A

N/A

N/A

1

* Adverse events

Limitations of the Results:
There are several important limitations on extrapolation of these data. First, some of the trials
looked at LGS or DS alone whereas some trials looked at a mix of LGS, DS, and other TREs. It is possible
that one type of seizure responds better to CBD than another, and this is skewing the results towards
favorability. In our opinion, this is less likely as the effect size was similar between all treatment groups,
regardless of seizure etiology and the theorized broad antiepileptic activity of cannabidiol. For example,
Laux et al. subgrouped LGS/DS patients from other TREs. At week 12, there was a median reduction in
monthly major motor seizures from baseline of 53% in the TRE group and 50% in the LGS/DS group.
Another limitation is that there was not a specific dose in several of the trials. Devinsky et al.
(2018A), Devinsky et al. (2017), and Thiele et al. (2018) had a set interventional dose of 20mg/kg.
However, Devinsky et al. (2016), Devinsky et al. (2018B), and Laux et al. (2019) allowed titratable doses
with significant variation. For example, Laux et al. allowed titratable doses from 25-50mg/kg. Laux et al.
also had the greatest median monthly reduction in motor seizure frequency (50% at 12 weeks) of the
trials studied. It is possible that patients that tolerated a higher dose of CBD received greater benefits. In
the Laux study, only 4/147 patients in the LGS/DS efficacy group withdrew due to adverse events, as did
25/433 in the other TRE group. However, 30/147 and 87/433 withdrew due to lack of efficacy; it is
unclear at which dose they withdrew, and it is possible that they were not able to achieve appropriate
dosing given AEs. In other words, the reason may be listed as lack of efficacy, but the cause of
withdrawal from the study may be inadequate dosing due to adverse events. This is relevant clinically as
patient tolerability is not yet predictable.
Lastly, we hypothesized that withdrawal from treatment may skew the results of cannabidiol
towards favorability. We examined the percentages of patients dropping out of treatment (compared to
placebo, when available). The results are summarized in Table 10. In placebo control trials, the rate of
withdrawal from treatment was significantly higher than the rate of withdrawal from placebo. The
primary reasons for withdrawal were lack of efficacy and adverse events. We compared this withdrawal
rate with the withdrawal rate from a trial of 68 patients with LGS (age range 2-26 years) treated with
clobazam, a preferred add-on medication for pediatric epilepsy.13 The rate of withdrawal in this trial was
15% (10 of 68)14. The primary cause was adverse events. We conclude that the rate of withdrawal in
these six studies was expected, but the lack of efficacy as a cause of withdrawal may be higher in CBD
trials and thus may skew results towards favorability.
Table 10: Disenrollment from Treatment by Trial
Study

# of Participants
Withdrawing

Total Participants

Percentage
Withdrawn from
Treatment (%)

Percentage
Withdrawn from
Placebo (%)

Devinsky et al.
(2018A)

9

76

11.8

2.6

Devinsky et al.
(2017)

9

61

14.8

5.1

Devinsky et al.
(2016)

10

137

7.3

N/A*

Laux et al. (2019)

10

152†

6.6

N/A*

Devinsky et al.
(2018B)

6

102

5.9

N/A*

Thiele et al. (2018)

14

86

16.3

1.2

*No placebo group was used as these were prospective cohort trials.
†For comparison, only the LGS/DS group at 12 weeks of treatment was used. Numbers were drawn
from the Safety Analysis Set rather than the Efficacy Analysis Set as that data was not published. The SAS
is larger than the EAS, so the percentage of subjects withdrawing may be greater.
Possible Biases:
There are several notable conflicts of interest in the studies, most involving GW
Pharmaceuticals, the producer of Epidiolex. Dr. Orrin Devinsky, the principal author of three of the
studies we examined, has served as a consultant, advisor, and investigator for GW Pharmaceuticals.
Another lead author, Linda Laux, is an investigator for GW Pharmaceuticals. Lastly, Elizabeth A. Thiele,
lead author of one of the RCTs looking at CBD and LGS, received grant money from GW Pharmaceuticals
as well as worked as a principal investigator for them prior to the study. There are several other authors
involved with previous employment with or received money from GW Pharmaceuticals.
Additionally, the use of extension trials in this review presents a concern for bias due to the
recruitment of participants from a previous CBD trial. We can assume that the participants enrolled into
the extension trials are more likely to have experienced a benefit with the drug and experienced few
adverse effects during the previous trial, potentially skewing the results in favor of the drug. The Laux et.
al. study shows a median 50% reduction in seizure frequency and the Devinsky 2018B study shows a
median 37.5% reduction in seizure frequency for an average of 43.8%, which compares to a mean of
40.3% reduction in seizure frequency in the high-dose groups of the other four non-extension trial
studies. While the difference between the mean frequency of seizure reduction is only 3.5% between
the extension vs. non-extension trials, it is still important to consider when evaluating for efficacy.
CONCLUSION:
In the management of treatment resistant LGS, DS, and other TRE syndromes, CBD used in
adjunct with traditional anti-epileptic therapy results in a clinically significant decrease in seizure
frequency compared to baseline. The three RCT’s included in this study showed significantly reduced
seizure frequency when compared to placebo. Although efficacious and generally well-tolerated, CBD
used in conjunction with AED’s has a high side effect profile, as evidenced by the high rates of adverse
events in each trial. While the rates of adverse events were high, few were considered severe and none
resulted in death. Small sample size, trial design, potential bias, inconsistent dosing between trials, and
conflicts of interest are all aspects that limited this review. Considerations for future studies include
additional RCT’s with larger sample sizes. If results are reproducible on a larger scale there is even more

reason to consider adding CBD to the standard treatment of LGS, DS, and TRE, keeping in mind the high
cost of the drug.
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